On November 4, 2025 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), reported its abstract highlighting immune mechanism-of-action data for its novel ADC payload, PH1. The abstract is now available on the 40th Annual SITC (Free SITC Whitepaper) Meeting website, and the Company will present the abstract in oral and poster presentations at the SITC (Free SITC Whitepaper) Annual Meeting being held November 5-9, 2025 in National Harbor, MD.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Utilizing its innovative ADC payload platform, Akari is advancing a new class of immuno-oncology ADCs built on the platform of a novel PH1 payload, a spliceosome modulator that has a unique preclinical efficacy and safety profile with the potential to address unmet need for oncology patients singly or in combination with checkpoint inhibitors.

The full SITC (Free SITC Whitepaper) abstract, which included 2 figures, is now available here with the results summarized as follows:

In this work, Akari investigates the mechanism behind preclinical colon tumor regressions induced by a Trastuzumab PH1 ADC with/without anti-PD-1 and contrasts that against a first-in-class ADC with a microtubule inhibitor payload. A higher rate of complete regressions in the PH1 ADC combination vs comparator ADC combination is attributed to an immune response stimulated by neoantigen, activation of antigen-presenting cells, B, and T-cells, and a mechanistic synergy between the PH1 payload and the checkpoint inhibitor. Interestingly, while neither single agent induced gamma-delta T cells, a kind of T-cell that is not limited by low neoantigen expression in tumors or low numbers of antigen-presenting cells, the PH1 ADC together with anti-PD-1 agent expanded this tumor-killing T-cell population.

Further details will be released in the poster and oral presentations. Details are as follows:

Title: A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential Beyond Cytotoxicity

Presenter: Satyajit Mitra Ph.D., Executive Director, Head of Oncology at Akari Therapeutics
Abstract No: 951
Poster Session: Exhibits & Poster Viewing 1 & 2
Date and Time: Friday, November 7, 2025,11:30 AM-12:15 PM ET and 5:35 PM-7:00 PM ET, respectively
Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
Oral Session: 302 Beyond Cytotoxic Chemotherapy: the Next Generation of ADCs for Immune Modulation
Date and Time: Sunday, November 9, 2025, 11:05-11:20 AM ET
Location: Gaylord National Resort and Convention Center – Ballroom Level – Potomac Ballroom

For more information about the SITC (Free SITC Whitepaper) Annual Meeting, please visit sitcancer.org. Additionally, for those registered to attend the conference, if you would like to schedule a meeting with Akari, please contact [email protected].

(Press release, Akari Therapeutics, NOV 4, 2025, View Source [SID1234659341])